Whitehawk Therapeutics Extends Runway with $87.5M Financing as Clinical Trials Progress — Whitehawk Therapeutics, Inc.

Event summary

$87.5M private placement equity financing in May 2026, extending runway into 2H 2028.
Phase 1 trials for HWK-007 and HWK-016 continue enrollment; HWK-206 trial initiation planned for Q3 2026.
Option agreement with Hangzhou DAC for access to CPT113 for up to five additional ADC programs.
Collaboration with Biocytogen for bispecific antibody ADC development using RenLite® platform.

The big picture

Whitehawk Therapeutics is positioning itself as a key player in the ADC space, leveraging strategic partnerships and financing to extend its clinical pipeline. The company's focus on advanced bioconjugation technologies and bispecific antibodies aligns with broader industry trends toward more targeted and effective cancer treatments. With $190M in cash reserves, Whitehawk aims to sustain its clinical execution while exploring new program opportunities.

What we're watching

Clinical Progress: Whether initial Phase 1 data for HWK-007 and HWK-016 in 1H 2027 will meet efficacy expectations.
Pipeline Expansion: The pace at which Whitehawk can deliver new ADC INDs within the next 12-24 months.
Financial Sustainability: How effectively the $87.5M financing will support operations into 2H 2028 given current R&D expenses.